CHMP extensions for Roche's Tarceva, Novartis' Afinitor and Wyeth's Enbrel
This article was originally published in Scrip
Executive Summary
Following its meeting on 21st July 2011, the Committee for Medicinal Products for Human Use (CHMP), advisers to the European Commission, gave a positive opinion on the use of Roche's Tarceva (erlotinib) as a first-line treatment in locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. The opinion, which was made public on 22 July, makes it clear that the CHMP believes that the drug has not demonstrated benefit in EGFR-negative tumours.